<?xml version="1.0" encoding="UTF-8"?>
<p id="Par130">Patient attitudes towards ASCT may have changed [
 <xref ref-type="bibr" rid="CR28">28</xref>], given the results of NCRI Myeloma X. Participants no longer have the option of not receiving ASCT on study. In addition, NICE guidance recommends second ASCT to eligible patients who have completed re-induction without PD and have a response duration of between 12 and 24 months after their first ASCT [
 <xref ref-type="bibr" rid="CR7">7</xref>]. These factors could contribute to participants and their treating physicians being more likely to agree to participate in ACCoRd, as the control arm is the basis of national standard-of-care second-line treatment for this patient group. In addition, participants are gaining access to treatment with ixazomib, currently not available outside of clinical studies.
</p>
